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Abstract
Background: Most systematic reviews have explored the efﬁcacy of treatments on symptoms associated with post-traumatic

stress disorder (PTSD), which is a chronic and often disabling condition. Previous network meta-analysis (NMA) had limitations such
as focusing on pharmacological or psychotherapies. Our review is aims to explore the relative effectiveness of both pharmacological
and psychotherapies and we will establish the differential efﬁcacy of interventions for PTSD in consideration of both symptom
reduction and functional recovery.
Methods: We will conduct a network meta-analysis of randomized controlled trials evaluating treatment interventions for PTSD. We

will systematically search Medline, PILOT, Embase, CINHAL, AMED, Psychinfo, Health Star, DARE and CENTRAL to identify trials
that: (1) enroll adult patients with PTSD, and (2) randomize them to alternative interventions or an intervention and a placebo/sham
arm. Independent reviewers will screen trials for eligibility, assess risk of bias using a modiﬁed Cochrane instrument, and extract data.
Our outcomes of interest include PTSD symptom reduction, quality of life, functional recovery, social and occupational impairment,
return to work and all-cause drop outs.
Results: We will conduct frequentist random-effects network meta-analysis to assess relative effects of competing interventions.
We will use a priori hypotheses to explore heterogeneity between studies, and assess the certainty of evidence using the GRADE
approach.
Conclusion: This network meta-analysis will determine the comparative effectiveness of therapeutic options for PTSD on both
symptom reduction and functional recovery. Our results will be helpful to clinicians and patients with PTSD, by providing a high-quality
evidence synthesis to guide shared-care decision making.
Abbreviations: CAPS = clinician-administered PTSD scale, CI = conﬁdence interval, DSM = diagnostic and statistical manual of

mental disorders, GRADE = grading of recommendations assessment, development, and evaluation, MCS = mental component
summary, NMA = network meta-analysis, PCS = physical component summary, PTSD = post-traumatic stress disorder, SUCRA =
surface under the cumulative ranking curve.
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suffer with PTSD in at some point in their lifetime.[28] In a
retrospective study of 44 PTSD claims awarded by the Workers
Compensation Board of British Columbia, Canada, only 43% of
disabled workers returned to their previous job 4 years after their
trauma, 23% returned to alternate employment, and 34% did not
returned to any type of work.[29] Similarly, a prospective study of
94 PTSD patients in Ontario, Canada, found 57% had not
returned to work in any capacity 9 months after their motor vehicle
accident; among the 43% who had, a little more than half (57%)
required job modiﬁcation.[30]
There is uncertainty regarding what treatments are most
effective for facilitating return-to-work among traumatized
workers. Existing systematic reviews focus on the effect of
selected therapies instead of exploring the relative effectiveness of
competing therapies, and on amelioration of PTSD symptoms
versus functional recovery.[31–37] A previous network metaanalysis (NMA) of pharmacological treatments for PTSD[38] has
a number of limitations, including:

1. Introduction
Post-traumatic stress disorder (PTSD) results from experiencing
or witnessing an emotionally traumatic event that is perceived to
present a threat to the life or physical integrity of one’s self or
others. PTSD is deﬁned by 8 criteria (Table 1),[1,2] including
exposure to a traumatic event and resulting symptoms from each
of 4 clusters:
(1)
(2)
(3)
(4)

intrusion,
avoidance,
negative alterations in cognitions and mood, and
alterations in arousal and reactivity.

The sixth criterion requires that symptoms have been present for
>1 month; the seventh assesses functioning (ie, symptoms interfere
with the ability to go about normal daily tasks); and the eighth
criterion is that symptoms are not attributable to another medical
condition.[3] Whereas some symptoms associated with PTSD (eg,
hypervigilance) function to maintain an ongoing sense that the
inciting event could happen again, which in turn, maintains fear
and avoidance,[4] others are associated with persistent feelings of
shame and guilt (eg, negative-trauma related emotions). The
diagnostic and statistical manual of mental disorders (DSM-5)[3]
also includes a dissociative subtype of PTSD, in recognition that
15% to 30% of patients with PTSD presents with symptoms of
depersonalization and derealization.[5–15]
The lifetime prevalence of PTSD among the general public is 8%
to 9%,[16–18] and between a quarter and a third of workers exposed
to traumatic events develop symptoms of PTSD.[19,20] Patients
suffering with PTSD experience social impairment, high absenteeism, unemployment[21–27] and work-related disability, particularly
when completing tasks requiring high concentration and cognitive
demands.[24–25] According to a 2016 review, 2.5 million of the
general population and 70,000 ﬁrst responders in Canada would

(1) an outdated search (February 2016),
(2) consideration of pharmacologic therapies only,
(3) narrow focus on exploring treatment effects for only
symptom reduction and all-cause drop-outs, and
(4) use of the surface under the cumulative ranking curve
(SUCRA) approach to rank interventions – an approach that
does not consider the quality of evidence, or the estimates of
precision around treatment effects.
Another NMA[39] was similarly limited by a narrow focus
only on psychotherapeutic approaches, an outdated search
(January 2011), time-restricted search strategies (1980–2010),
inclusion of trials with patients who had subclinical or subthreshold PTSD and treatment effects limited to only symptom
reduction.

Table 1
DSM 5-criteria for PTSD with description.
Diagnostic criteria

Description

Criteria A (1 symptom
required)

Exposure to trauma

Exposure to event (involved or witnessed) that posed a threat of death, serious injury, or sexual violence.
Learning that a close relative or close friend was exposed to trauma.
Person experiences helplessness, horror, and intense fear to aversive details, which may be part of their work.
For example, ﬁrst responders or paramedics

Criteria B
(1 symptom required)

Re-experiencing
symptoms/ ﬂash backs

Recurrent intrusive thoughts or recollection of memories of the traumatic event, nightmares, ﬂash backs and
intense fear/ reaction to both internal and external reminders

Criteria C (1 required)

Avoidance

Persistent avoidance of stimulus associated with trauma such as avoiding distressing memories, or avoiding
people, places, conversations, activities or situations

Criteria D
(2 symptom required)

Cognitive deﬁcit

Persistent numbing such as alteration in mood, cognitions that are associated with traumatic event such as
inability to recall key features of the traumatic event, negative thoughts about one self, persistent negative
trauma-related emotions, diminished interest

Criteria E
(2 symptom required)

Hyper arousal

Sleep impairment, nightmares and reactivity associated with the traumatic event, irritability, aggressive behavior,
exaggerated startle response

Criteria F

Duration

Symptoms are present for more than 1 month

Criteria G

Functional Impairment

Symptoms are associated with persistent functional impairment, social and occupational impairment

Criteria H

Exclusion

Not due to medication, substance use or illness

Two speciﬁcations

Dissociative features

Depersonalization: persistent feeling of detachment from one’s mental processes or body as if one were in dream
Derealization: experiencing distortion or detachment from reality
Full diagnostic criteria are not met until at least 6 months after the event

With delayed speciﬁcations

This table is adapted from the DSM 5 criteria from the American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.
DSM = diagnostic and statistical manual of mental disorders, PTSD = post-traumatic stress disorder.
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2.3. Data abstraction

As existing reviews of treatment for PTSD have largely
focussed on individual treatment’s effect on symptom reduction
and none have compared all treatments against each other. Due
to which there exist considerable uncertainty regarding what
treatments are effective for promoting symptom control and
functional recovery. Our proposed NMA will evaluate all
treatments for PTSD, provide relative effectiveness of treatments,
and evaluate the quality of the evidence in a thorough and
consistent manner using the grading of recommendations
assessment, development, and evaluation (GRADE) approach.

To help ensure the reliability of independent data extraction, we
will begin by piloting our data extraction form and then we will
conduct calibration exercises between reviewers. Data abstraction will be guided by a detailed instruction manual generated
from our piloting and calibration exercises. Teams of reviewers
will extract data independently and in duplicate from eligible
trials and resolve discrepancies through discussion. Data
abstracted will include study characteristics (the ﬁrst author,
publication year, funding source); patient and trial characteristics
such as sample size, participant demographics (age, gender,
litigation and disability status of the participants, associated comorbid psychological and substance status, traumatic brain
injury and ﬁrst responder status such as veterans, police ofﬁcers
and ﬁre ﬁghters); characteristics of interventions and comparators (dose of pharmacological treatments, frequency for nonpharmacologic treatments, use of other intervention such as
medications or psychotherapies during the trial).
We will extract data on the on return to work (percent patients
on partial or complete sick leave, percent patients with partial or
complete functional recovery). We will also extract data on the
PTSD symptoms such as reported with clinician-administered
PTSD scale (CAPS),[41–43] PTSD checklist[44] or any other
validated scales, quality of life such as short-form 36 with
Physical (PCS) and mental (MCS) component summaries,[45] or
any other validated quality of life scale such as the World Health
Organization Quality of Life Questionnaire,[46] The Quality of
Life Enjoyment and Satisfaction Questionnaire[47]; functional
impairment with Sheehan’s disability scale,[48] and social and
occupational impairment with any validated scale such as social
adjustment scale.
If an individual trial reports more than 1 outcome in a common
domain (eg, return to work), we will select only 1 outcome per
domain based on the following criteria:

2. Methods
We registered our protocol on PROSPERO (CRD42018072682).
Our review will conform to the PRISMA Extension Statement for
Reporting of Systematic Reviews Incorporating Network Metaanalyses of Health Care Interventions.[40]
2.1. Search strategy
We identiﬁed all relevant randomized trials, in any language,
through a systematic search of published international literature
on traumatic stress, CINAHL, EMBASE, MEDLINE, AMED
allied and complementary medicine, HealthSTAR, database of
abstracts of reviews of effects, PsychINFO, and the Cochrane
Central Registry of Controlled Trials (Appendix#1). An experienced medical librarian reﬁned our search strategy for each
database. Reviewers scanned the bibliographies of all eligible
trials and other relevant publications for additional trials. We did
not have any language restriction.
2.2. Eligibility criteria and study selection
Trials were eligible if they enrolled adult patients diagnosed with
primary or secondary PTSD according to operationalized criteria
such as DSM criteria, international classiﬁcation of diseases
criteria, or clinician diagnosed and randomized them to any
pharmacologic (monotherapy or add-on therapy) or nonpharmacologic treatment strategy compared to an alternative
treatment, their combinations, placebo or control. Eligible
pharmacologic interventions included but were not restricted
to antidepressants such as selective serotonin inhibitor, nonselective serotonin inhibitors, anxiyoltics, antipsychotics, and
antiepileptics or mood stabilizers. Eligible nonpharmacologic
interventions included but were not restricted to: cognitive
behavioral therapy, exposure therapy, yoga, supportive therapy,
and eye movement desensitization and reprocessing.
We will exclude trials with less than 10 participants per arm,
pilot or feasibility or preliminary studies, and cross-over trials. We
will also exclude trials in which the population does not constitute
100% PTSD patients including sub-threshold or subclinical or
partial PTSD. We will also exclude studies that enrolled patients
suffering with acute stress disorders. Conference abstracts and
rarely used interventions or interventions that are discontinued due
to serious adverse effects (such as Nefazadone, Brofaromine) rarely
used for interventions in North America will be excluded.
Using standardized forms, reviewers will work independently
in duplicate to screen title and abstracts, and the full text of all
potentially eligible studies. Before starting literature screening, all
reviewers will complete a pilot exercise to ensure understanding
of the process and improve reliability. Any discrepancies will be
resolved through consensus between reviewers or with the help of
an adjudicator.

(1) most commonly used outcome measure across eligible trials;
(2) most validated outcome; or
(3) most precise estimate of treatment effect.
After consulting with our expert panel members, the CAPS will
be preferred over any other scale for assessing PTSD symptoms.
In the case of multiple follow-ups, we will collect data on the
longest follow-up.
2.4. Risk of bias assessment
Reviewers will assess risk of bias among the eligible studies using
the Cochrane risk of bias instrument that has modiﬁed response
options of “deﬁnitely or probably yes” – considered as low risk of
bias – or “deﬁnitely or probably no” – considered as high risk of
bias.[49] We will evaluate the following risk of bias issues: random
sequence generation, allocation concealment, blinding of study
participants, personnel, outcome assessors, and data analysts;
selective reporting, and incomplete outcome data (>20% missing
participant’s data).[50] We will assess risk of bias for each
outcome separately on a component-by-component basis.[51]
2.5. Data synthesis
We will do drug adjudication to collapse similar interventions or
drugs belonging to the same class into 1 treatment node. For
dichotomous outcomes (eg, percent patients on partial or
complete sick leave, percent patient with partial or complete
3
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“moderate,” “low,” or “very low.” The starting point for
certainty in estimates from randomized trials is high, but maybe
rated down based on limitations in risk of bias, imprecision,
inconsistency, and indirectness, and publication bias.[63]
We will follow detailed guidance that the GRADE working
group has provided for rating the quality of treatment effect
estimates from network meta-analysis.[62] In brief, the rating
consists of 4 steps: ﬁrst, we will present direct and indirect
treatment estimates for each comparison of the evidence network.
The direct estimate of effect is provided by a head-to-head
comparison (trials of A vs B), and the indirect estimate is provided
by 2 or more head-to-head comparisons that share a common
comparator (for example, we infer the effects of A vs B from trials
of A vs C and trials of B vs C). Second, we will rate the quality of
each direct and indirect effect estimate; third, we will present the
NMA estimate for each comparison of the evidence network and
ﬁnally, we will rate the quality of each NMA effect estimate.
We will base hierarchy of the treatment options in the NMA
according to 3 categories:

functional recovery), we will calculate relative risk and absolute
risk (using baseline risk estimates from the control arm of eligible
studies), and the associated 95% conﬁdence intervals (CIs) for
outcomes. For studies reporting continuous outcomes (eg, PTSD
symptom severity, quality of life such as SF-36 (PCS and MCS),
disability, social, and occupational impairment when the same
instrument is used, we will calculate the weighted mean
difference, and the associated 95% CIs. For trials that use
different instruments for the same underlying construct such as
functional recovery, we will convert all outcomes to a common
instrument based on the recommendations by Thorlund et al.[52]
We will contact study authors in case data is not completely
reported or will use methods suggested by Cochrane handbook[53] and Hozo et al[54] to impute missing standard deviations
when P-values, t-values, CIs, range, or standard errors (SEs) are
reported in articles.
2.6. Methods for direct comparisons
We will perform standard pairwise meta-analyses using the
DerSimonian–Laird random-effects model for all outcomes with
at least 2 studies.[55] We will determine statistical heterogeneity
using the Q statistic and I2. For each direct comparison, we will
report study and participant characteristics, risk of bias ﬁndings,
and pooled estimates for outcomes of interest.

(1) those that are clearly superior;
(2) those with intermediate effectiveness, and
(3) those that are inferior.
Treatments no better than placebo will be categorized in the
lowest tier; treatments better than placebo will be categorized in the
intermediate tier; whereas those superior to at least 1 tier 1
treatment will be judged superior. Furthermore, treatments will be
categorized according to the quality of evidence such as high and
moderate versus low or very low. Interventions with high quality or
moderate evidence will be ranked as either “among the most
effective,” “inferior to the most effective/superior to the least
effective,” or “among the least effective.” Interventions supported
by low or very low quality evidence will be ranked into the same 3
categories but prefaced with “may be” to acknowledge the reduced
conﬁdence in supporting evidence (eg, “may be among the most
effective”) and will be presented separately from those supported
by moderate or high quality evidence.
We will assess small study effects in direct comparisons using
the Harbord test for dichotomous outcomes and the Egger test for
continuous outcome when at least 10 studies are available.[62,64]

2.7. Methods for multiple treatment comparisons (NMA)
To assess the comparative effectiveness of competing treatments,
we will perform random-effects NMA using the frequentist
approach.[56–59]
Although the assumptions for NMA are similar to conventional meta-analysis, key extra assumptions are transitivity (there
are no effect modiﬁers inﬂuencing the indirect comparisons) and
coherence, (direct and indirect effect estimates are similar).[60] We
will identify incoherence comparing direct evidence (ie, estimates
from pairwise comparisons) with indirect evidence (ie, estimates
form network meta-analysis) using the node splitting method. In
this approach, the incoherence will be assessed locally within
each closed loop of the network separately as the difference
between direct and indirect estimates for a speciﬁc comparison in
the loop.[56–57] We will use a Wald test to test any statistical
difference between the direct and the indirect estimates.[57]
We will report our ﬁndings with probability statements of
intervention effects. Probability rankings allow us to report a
chance percentage of which interventions rank higher; however,
simplifying the results of a network down to probabilities can
lead to misinterpretations, speciﬁcally, when particular comparisons (ie, nodes) are not well-connected and/or when certainty in
evidence varies between comparisons. Following display of the
rank probabilities using rankogram, we will use the SUCRA to
aid in the interpretation of relative effect of the interventions; an
intervention with a SUCRA value of 100 is certain to be the best,
whereas an intervention with 0 is certain to be the worst.[52] We
will use STATA (StataCorp, Release 15.1, College Station, TX)
for statistical analyses.

2.9. Subgroup and sensitivity analyses
We will test 7 a priori hypotheses to explain variability between
studies:
(1) patients in receipt of disability beneﬁts and/or involved in
litigation will show smaller effects than those not so involved;
(2) trials at high risk of bias will show larger effects compared to
trials at low risk of bias;
(3) trials with longer follow-up will show smaller treatment
effects;
(4) trials that enrolled patients formally diagnosed with PTSD
according to validated criteria (eg, DSM-III, DSM IV, DSM
IV-R, DSM-5, CAPS, or symptom severity measures) will
show smaller effects than trials that do not require formal
diagnosis;
(5) military and ﬁrst-responder samples with PTSD will show
smaller effects than civilian samples;
(6) patients with PTSD and co-morbid substance abuse will show
smaller effects than patients with PTSD without co-morbid
substance abuse;

2.8. Certainty (quality) of evidence
We will use the GRADE approach to rate the certainty in
evidence of direct, indirect, and network estimates[61–64] on an
outcome-by-outcome basis that classiﬁes evidence as “high,”
4
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(7) patients with PTSD and co-morbid traumatic brain injury will
show smaller effects than patients with PTSD without comorbid traumatic brain injury.
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